PhaseBio Pharmaceuticals Return on Tangible Assets

Return on Tangible Assets of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Return on Tangible Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Return on Tangible Assets for 2020 was -278.9% (a 425.73% increase from previous year)
  • Annual Return on Tangible Assets for 2019 was -53.05% (a 29.93% increase from previous year)
  • Annual Return on Tangible Assets for 2018 was -40.83% (a -114.13% decrease from previous year)
  • Twelve month Return on Tangible Assets ending September 29, 2021 was -210.52% (a 59.29% increase compared to previous quarter)
  • Twelve month trailing Return on Tangible Assets decreased by -24.52% year-over-year
Trailing Return on Tangible Assets for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-210.52% -132.16% -132.01% -278.9%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Return on Tangible Assets of PhaseBio Pharmaceuticals

Most recent Return on Tangible Assetsof PHAS including historical data for past 10 years.

Interactive Chart of Return on Tangible Assets of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Return on Tangible Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -278.9%
2019 -53.05%
2018 -40.83%
2017 288.89%
2016 -286.16%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.